Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

MLA

Mei-Fang Li, et al. “Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer with Brain Metastases: A Retrospective Cohort Study.” Cancer Management and Research, vol. 11, Mar. 2019, pp. 2129–38. EBSCOhost, https://doi.org/10.2147/cmar.s184922.

APA

Mei-Fang Li, Jinghui Lin, Ren-Jang Lin, Zhiyong He, & Dong Lin. (2019). Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Management and Research, 11, 2129–2138. https://doi.org/10.2147/cmar.s184922

Chicago

Mei-Fang Li, Jinghui Lin, Ren-Jang Lin, Zhiyong He, and Dong Lin. 2019. “Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer with Brain Metastases: A Retrospective Cohort Study.” Cancer Management and Research 11 (March): 2129–38. doi:10.2147/cmar.s184922.